Related Experiment Videos
Update in oncology
1University of Pennsylvania, Philadelphia, USA.
Annals of Internal Medicine
|September 24, 2004
Summary
No abstract available in PubMed .
Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2011
Same author
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2008
Same author
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2008
Same author
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Cancer research·2007
Same author
Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura.
Journal of clinical apheresis·2003
Same journal
The Role of Telemedicine on Interhospital Transfer Outcomes : A Systematic Review.
Annals of internal medicine·2026
Same journal
Prolonged Short Sleep and Its Effect on Body Weight and Composition : A Pooled Analysis of Randomized Trials.
Annals of internal medicine·2026
Same journal
In AF, LAAC was noninferior to NOAC therapy for a composite efficacy outcome and reduced non-procedure-related bleeding at 3 y.
Annals of internal medicine·2026
Same journal
In adults with COPD, the BLISS score predicted risk for acute respiratory hospital admission at 2 y.
Annals of internal medicine·2026
Same journal
In AF at risk for stroke and bleeding, LAAC was not noninferior to medical therapy for a composite of thromboembolic and safety events.
Annals of internal medicine·2026